Boston Scientific Corporation $BSX Shares Bought by Relyea Zuckerberg Hanson LLC

Relyea Zuckerberg Hanson LLC boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 2.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 15,340 shares of the medical equipment provider’s stock after purchasing an additional 417 shares during the period. Relyea Zuckerberg Hanson LLC’s holdings in Boston Scientific were worth $1,648,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC raised its stake in Boston Scientific by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after acquiring an additional 3,932 shares during the last quarter. Bank of New Hampshire increased its holdings in shares of Boston Scientific by 552.0% in the second quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock valued at $2,119,000 after purchasing an additional 16,699 shares during the period. MRA Advisory Group purchased a new position in shares of Boston Scientific in the second quarter worth about $273,000. NS Partners Ltd lifted its holdings in shares of Boston Scientific by 1.6% during the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock worth $37,143,000 after purchasing an additional 5,704 shares during the period. Finally, Neville Rodie & Shaw Inc. boosted its position in Boston Scientific by 95.9% in the second quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider’s stock valued at $4,883,000 after buying an additional 22,255 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. The trade was a 58.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $17,972,457 over the last 90 days. 0.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Leerink Partners raised their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Truist Financial boosted their target price on shares of Boston Scientific from $125.00 to $129.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Finally, Raymond James Financial boosted their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a report on Thursday, July 24th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $120.79.

Boston Scientific Trading Up 1.1%

BSX stock opened at $97.30 on Monday. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market cap of $144.17 billion, a P/E ratio of 57.91, a PEG ratio of 2.34 and a beta of 0.61. The company’s 50-day simple moving average is $102.93 and its 200-day simple moving average is $102.06.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.